Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 20, 2010

Pfizer Pays Phylogica $500K Up-Front in Vaccine Discovery Deal

  • Phylogica entered into a collaboration and licensing agreement with Pfizer to discover novel peptide-based vaccines. In the deal, Phylogica will receive an up-front payment of $500,000. In addition, Phylogica is eligible to receive a commercial license payment and is also eligible to receive preclinical, clinical, and other milestone payments of up to $134 million as well as royalties on worldwide sales.

    Under the agreement, Phylogica will employ its Phylomer® drug-discovery platform to identify Phylomer peptides suitable for further evaluation. Phylogica is granting Pfizer certain rights including an option to license any resulting Phylomers for further research, development, and commercialization of novel peptide-based vaccines derived from such Phylomers.

    “This alliance supports the potential utility of Phylogica’s Phylomer drug-discovery platform for peptide-based drug discovery. With the present announcement, Phylogica has now entered into three alliances with global pharmaceutical companies within the last 12 months,” says Paul Watt, Ph.D., founder and CEO of Phylogica.

    Phylomer peptides are derived from biodiverse natural sequences, which have been selected by evolution to form stable structures, which can bind tightly and specifically to disease-associated target proteins both inside and outside cells, according to Phylogica. Suitable targets for blockade by Phylomers include protein interactions that promote multiple diseases such as infectious diseases, cancer, autoimmunity, and heart disease.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »